No Data
No Data
No Data
No Data
No Data
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on...
PR NewswireApr 24 07:05 ET
Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug
Seeking AlphaApr 23 10:29 ET
REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 28%
REGENXBIO Inc. (NASDAQ:RGNX) shares have retraced a considerable 28% in the last month, reversing a fair amount of their solid recent performance. The drop over the last 30 days has capped off a to
Simply Wall StApr 19 06:29 ET
Regenxbio(RGNX.US) Officer Sells US$272.87K in Common Stock
$Regenxbio(RGNX.US)$ Officer Mills Kenneth T. sold 15,000 shares of common stock on Apr 15, 2024 at an average price of $18.1914 for a total value of $272.87K.Source: Announcement What is statement of
moomoo NewsApr 17 17:48 ET
REGENXBIO Is Maintained at Buy by Stifel
REGENXBIO Is Maintained at Buy by Stifel
Dow JonesApr 12 12:03 ET
Where Regenxbio Stands With Analysts
Analysts' ratings for Regenxbio (NASDAQ:RGNX) over the last quarter vary from bullish to bearish, as provided by 9 analysts.The following table encapsulates their recent ratings, offering a glimpse in
BenzingaApr 12 12:01 ET
No Data
No Data